Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Neurim Pharmaceuticals Ltd. is a neuroscience drug discovery and development company. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 by Nava Zisapel and Yehuda Zisapel and is headquartered in Tel-Aviv, Israel.

Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen. Their company focuses its small-molecule drug discovery expertise in Liver and Gastrointestinal disease areas and has now recently entered the field of Cancer Therapy. They not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities. Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules.

Lek Pharmaceuticals dd, a subsidiary of Novartis AG, is a company headquartered in Ljubljana, Slovenia, that develops, manufactures and markets drugs and pharmaceutical products. Robert Ljoljo is the CEO, in this role since 2019. On November 21, 2002 Novartis AG acquired Lek Pharmaceuticals dd for $689.24 million.

TaiwanJ Pharmaceuticals Co., Ltd. engages in new medical research activities. It offers drug testing, biotechnology services, and sale of western medicine. The company was founded by Sen Chou Wu on May 2, 2011 and is headquartered in Hsinchu, Taiwan.

Miles Laboratories, Inc., part of Bayer AG, is a company headquartered in Rexdale, ON, Canada, that manufactures pharmaceutical products.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Engages in priniting activities

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA.

Dow manufactures and sells chemicals, plastic materials, and agricultural services. They deliver products and services to customers in electronics, water, energy, coatings, and agriculture. They specialize in materials science to deliver solutions for customers in packaging, infrastructure, and consumer care.

Omnichem Co., Ltd. is a South Korean private company located in Daejeon City. The firm manufactures UV hard coatings for optical films.

Suzhou Pengxu Pharmaceutical Technology Co., Ltd., established on 2011-07-07, Business scope includes research and development of pharmaceutical intermediates,Sales;API,new medical research;new material technology,biomedical technology,Software technology research and development,consult,Services and Transfers;Chemical product sales(Excluding hazardous chemicals),Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(The above related licenses can only be operated after obtaining the license)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Visolis, a bioengineering company, develops carbon-negative and sustainable chemicals. Its systems approach integrates innovations in synthetic biology, chemical catalysis, and process scale-up to enable new bio-based manufacturing platforms. Visolis' bio-based process helps in achieving true carbon negative chemical synthesis. It began operation in 2012, with its headquarters in Berkeley in California.

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.